IPHA

Innate Pharma

9 hedge funds and large institutions have $179K invested in Innate Pharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
3
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Shares
Change %
Morgan Stanley
1
Morgan Stanley
New York
$93K +$14K +7,700 +18%
Citadel Advisors
2
Citadel Advisors
Florida
$46.6K +$4.11K +2,350 +10%
Millennium Management
3
Millennium Management
New York
$20.4K -$6.41K -3,665 -24%
UBS Group
4
UBS Group
Switzerland
$10.8K -$5.52K -3,044 -34%
GI
5
GAMMA Investing
California
$6.27K +$2.22K +1,223 +55%
Barclays
6
Barclays
United Kingdom
$1K
RhumbLine Advisers
7
RhumbLine Advisers
Massachusetts
$822 -$359 -205 -30%
Optiver Holding
8
Optiver Holding
Netherlands
$177
PS
9
Principal Securities
Iowa
$82 +$82 +45 New
ETC
10
Exchange Traded Concepts
Oklahoma
-$112K -62,752 Closed
TRCT
11
Tower Research Capital (TRC)
New York
-$5 -3 Closed